Bestron0.45 mg + 20 mg

Established (FDA-Approved) Indications

• Treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause.
• Prevention of postmenopausal osteoporosis in women with a uterus, for whom treatment options that do not contain estrogen are considered inadequate.

Important Population Restriction

Bestron is specifically formulated for women who have a uterus, because the bazedoxifene component in Bestron protects the lining of the uterus (endometrium) against estrogen-related overgrowth, removing the need for a separate progestin. Bestron is not indicated for women who have had a hysterectomy (no uterus), since a separate progestin is not required in that group and combined estrogen-only products are typically used instead.

Not Indicated / Off-Label

Bestron is not indicated for contraception, for use in premenopausal women, or for prevention of cardiovascular disease or dementia; clinical evidence does not support benefit for these uses and, for cardiovascular disease and dementia, suggests possible harm (see Precautions and Warnings).

Each tablet of Conjugated Estrogen + Bazedoxifene contains:

• Conjugated Estrogens 0.45 mg
• Bazedoxifene (as bazedoxifene acetate) 20 mg

Formulated as an oral, film-coated tablet for once-daily administration.

Bestron is a tissue-selective estrogen complex (TSEC) that pairs conjugated estrogens with bazedoxifene, a selective estrogen receptor modulator (SERM). It is prescribed to relieve moderate-to-severe hot flashes of menopause and to help prevent postmenopausal osteoporosis in women who still have a uterus. Unlike traditional estrogen-progestin hormone therapy, Bestron does not require a separate progestin, because the bazedoxifene component itself provides endometrial protection while allowing the estrogen component to relieve vasomotor symptoms and preserve bone density.

Bestron belongs to the Tissue-Selective Estrogen Complex (TSEC) class - a combination of an estrogen (conjugated estrogens) with a Selective Estrogen Receptor Modulator (SERM, bazedoxifene). It falls broadly under hormone replacement therapy (HRT) agents used in menopause management.

Mechanism of Action

Conjugated Estrogen + Bazedoxifene combines two active components with complementary, tissue-selective effects:

• Conjugated estrogens bind and activate estrogen receptors throughout the body, replacing declining endogenous estrogen after menopause. This reduces the frequency and severity of hot flashes and helps maintain bone mineral density by reducing bone resorption.
• Bazedoxifene, a third-generation SERM, acts as an estrogen-receptor antagonist in the uterus, blocking the endometrial proliferation that estrogen alone would otherwise cause. This endometrial protection is what allows Conjugated Estrogen + Bazedoxifene to be used without an added progestin in women with a uterus.

Pharmacokinetics (brief)

Conjugated estrogens are absorbed orally and undergo extensive hepatic metabolism, mainly via sulfation and CYP3A4-mediated pathways. Bazedoxifene is absorbed orally, extensively glucuronidated in the liver/intestine, and eliminated predominantly via feces. Both components of Conjugated Estrogen + Bazedoxifene are taken together once daily as a fixed-dose tablet.

Bestron is taken by mouth, once daily, with or without food, preferably at the same time each day to maintain consistent hormone levels. Swallow the tablet whole; it should not be split, crushed, or chewed unless otherwise directed by a physician.

• CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): may increase metabolism of the estrogen component of Bestron, reducing its effectiveness.
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, certain protease inhibitors): may increase circulating estrogen levels from Bestron, potentially increasing the risk of estrogen-related side effects.
• Bile acid sequestrants (e.g., cholestyramine): may reduce absorption of the bazedoxifene component of Bestron; if co-administration is necessary, separate dosing times.
• Grapefruit juice: may increase circulating estrogen levels; avoid excessive intake while taking Bestron.
• Thyroid hormone replacement: estrogens can increase thyroid-binding globulin, so patients on thyroid replacement therapy taking Bestron may need dose monitoring.

This list covers well-established, clinically significant interactions; it is not exhaustive. Inform your physician of all medicines, supplements, and herbal products you are taking before starting Bestron.

Common Side Effects

• Muscle spasms/leg cramps
• Nausea
• Diarrhea
• Dyspepsia (indigestion)
• Upper abdominal pain
• Oropharyngeal (throat) pain
• Dizziness
• Neck pain and back pain

Serious but Less Common Effects

See Precautions and Warnings for serious cardiovascular, thromboembolic, and gallbladder risks associated with Bestron. Contact a physician promptly for calf pain/swelling, sudden chest pain, sudden severe headache, vision changes, or signs of an allergic reaction.

Pregnancy: Bestron is intended solely for use in postmenopausal women and is contraindicated in pregnancy. There is no indication for Bestron during pregnancy, and it should be discontinued immediately if pregnancy is diagnosed or suspected. Use only if clearly needed and only in the approved postmenopausal population; consult a physician immediately if pregnancy occurs.

Lactation: Bestron is not indicated for use in breastfeeding women, as it is approved only for postmenopausal use. Estrogens can reduce milk production and pass into breast milk; Bestron should not be used while breastfeeding unless a physician determines there is a specific, clearly justified need, with potential benefit judged to outweigh potential risk to the infant.

Boxed Warning

Estrogen-containing therapies similar to the estrogen component of Bestron have been associated, in large clinical trials (the Women's Health Initiative), with an increased risk of cardiovascular disorders (myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism) and probable dementia in postmenopausal women 65 years of age or older. Bestron should be used at the lowest effective dose and for the shortest duration consistent with treatment goals, with periodic reassessment of the need for continued therapy.

Other Precautions

• Cardiovascular and thromboembolic risk: Individualize the decision to use Bestron based on symptom severity and personal cardiovascular/thromboembolic risk factors; discontinue promptly if a thromboembolic or vascular event occurs or is suspected.
• Population restriction: Bestron is designed for women with a uterus, since the bazedoxifene component provides endometrial protection without a separate progestin; it is not indicated for women without a uterus.
• Gallbladder disease: Estrogen therapy, including Bestron, is associated with an increased risk of gallbladder disease requiring surgery.
• Rebound symptoms: Hot flashes and other vasomotor symptoms may temporarily worsen upon discontinuing Bestron.
• Elevated triglycerides: Monitor patients with pre-existing hypertriglyceridemia, as estrogens in Bestron may raise triglyceride levels.

See Contraindications for absolute contraindications to Bestron.

There is limited clinical experience with overdose of Bestron. Overdose may present with nausea, vomiting, breast tenderness, abdominal pain, dizziness, fatigue, or withdrawal-type vaginal bleeding. There is no specific antidote for Bestron overdose. If overdose is suspected, seek immediate medical attention or contact a poison control center; treatment should be supportive and symptomatic under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly (≥65 years): Women 65 years of age or older taking Bestron have an increased risk of cardiovascular events and probable dementia (see Precautions and Warnings/Boxed Warning); use the lowest effective dose and reassess regularly.
• Hepatic impairment: Bestron is contraindicated in women with known liver impairment or liver disease (see Contraindications).
• Renal impairment: No specific dose adjustment of Bestron has been established; use with caution and clinical judgment.
• Pediatric population: Bestron is not indicated for use in children; it is approved only for postmenopausal women (see Pediatric Uses).
• Women without a uterus: Bestron is not indicated, since its endometrial-protective mechanism is unnecessary in this group.

Bestron should be used at the lowest effective dose and for the shortest duration consistent with the patient's treatment goals for vasomotor symptom relief or osteoporosis prevention. Physicians should periodically reassess (at least annually) whether continued treatment with Bestron is still needed, weighing symptom control and bone health benefits against cardiovascular, thromboembolic, and other risks that increase with age and duration of use.

Conjugated Estrogen + Bazedoxifene is classified under: Estrogens; Selective Estrogen Receptor Modulators (SERMs); Tissue-Selective Estrogen Complex (TSEC) - combination hormone therapy for menopause.

Conjugated Estrogen + Bazedoxifene works through two complementary mechanisms: the conjugated estrogens component activates estrogen receptors to relieve vasomotor symptoms and reduce bone resorption, while the bazedoxifene (SERM) component selectively blocks estrogen's proliferative effect on the uterine lining. This tissue-selective pairing lets Conjugated Estrogen + Bazedoxifene deliver estrogen's benefits for hot flashes and bone density while protecting the endometrium, eliminating the need for a separate progestin.

X (legacy FDA pregnancy category) - contraindicated in pregnancy; not indicated for use in premenopausal or pregnant women.

Bestron is not indicated for use in children or adolescents. It is approved solely for postmenopausal women, and safety and efficacy of Bestron in pediatric populations have not been established.